Clinical Effect of Rebamipide on Chronic Gastritis

BangMao Wang180 enrolled

Overview

To investigate the clinical effect of rebamipide in chronic gastritis patients. Patients with chronic gastritis were randomly divided into the experimental group and the control group. The experimental group were treated with rebamipide 0.1g tid and optimization of life style, and the control group were only optimized their life style for 26 weeks. Upper gastrointestinal endoscopy was performed in all patients to evaluate the severity of gastritis by modified Lanza score (MLS) and the histology by the updated Sydney system before and after treatment.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

180

Conditions

Gastritis

Interventions

RebamipideDRUG

Rebamipide is a

optimization of life styleBEHAVIORAL

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * With the symptoms as follow: epigastric pain, abdominal discomfort, abdominal distention, poor appetite, nausea, vomiting and so on * diagnosed as chronic gastritis with endoscopic and pathological methods * agree to join in this clinical trail Exclusion Criteria: \-

Outcomes

Primary Outcomes

modified Lanza score

Time frame: 26 weeks

visual Analog scale

to describe the inflamamtory of gastric mucosa pathologically

Time frame: 26 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.